• Product name
  • Description
    Rabbit polyclonal to KCNQ2
  • Host species
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Rabbit, Horse, Chicken, Guinea pig, Cow, Cat, Dog, Zebrafish
  • Immunogen

    Synthetic peptide corresponding to a region within N terminal amino acids 154-203 (YRGWRGRLKF ARKPFCVIDI MVLIASIAVL AAGSQGNVFA TSALRSLRFL) of Human KCNQ2 (NP_004509).

  • Positive control
    • HepG2 cell lysate



Our Abpromise guarantee covers the use of ab105511 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 96 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.


  • Function
    Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. KCNQ2/KCNQ3 current is blocked by linopirdine and XE991, and activated by the anticonvulsant retigabine. Muscarinic agonist oxotremorine-M strongly suppress KCNQ2/KCNQ3 current in cells in which cloned KCNQ2/KCNQ3 channels were coexpressed with M1 muscarinic receptors.
  • Tissue specificity
    In adult and fetal brain. Highly expressed in areas containing neuronal cell bodies, low in spinal chord and corpus callosum. Isoform 2 is preferentially expressed in differentiated neurons. Isoform 6 is prominent in fetal brain, undifferentiated neuroblastoma cells and brain tumors.
  • Involvement in disease
    Defects in KCNQ2 are the cause of benign familial neonatal seizures type 1 (BFNS1) [MIM:121200]. A disorder characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. Some rare cases manifest an atypical severe phenotype associated with epileptic encephalopathy and psychomotor retardation. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset. In some patients, neonatal convulsions are followed later in life by myokymia, a benign condition characterized by spontaneous involuntary contractions of skeletal muscles fiber groups that can be observed as vermiform movement of the overlying skin. Electromyography typically shows continuous motor unit activity with spontaneous oligo- and multiplet-discharges of high intraburst frequency (myokymic discharges). Some patients may have isolated myokymia.
    Defects in KCNQ2 are the cause of epileptic encephalopathy early infantile type 7 (EIEE7) [MIM:613720]. EIEE7 is an autosomal dominant seizure disorder characterized by infantile onset of refractory seizures with resultant delayed neurologic development and persistent neurologic abnormalities.
  • Sequence similarities
    Belongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.2/KCNQ2 sub-subfamily.
  • Domain
    The segment S4 is probably the voltage-sensor and is characterized by a series of positively charged amino acids at every third position.
  • Post-translational
    In Xenopus oocytes KCNQ2/KCNQ3 heteromeric current can be increased by intracellular cyclic AMP, an effect that depends on phosphorylation of Ser-52 in the N-terminus region.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • BFNC antibody
    • BFNS1 antibody
    • EBN 1 antibody
    • EBN antibody
    • EBN1 antibody
    • EIEE7 antibody
    • ENB 1 antibody
    • ENB1 antibody
    • HNSPC antibody
    • KCNA 11 antibody
    • KCNA11 antibody
    • KCNQ 2 antibody
    • Kcnq2 antibody
    • KCNQ2_HUMAN antibody
    • KQT like 2 antibody
    • KQT-like 2 antibody
    • KV7.2 antibody
    • KVEBN 1 antibody
    • KVEBN1 antibody
    • KvLQT 2 antibody
    • KvLQT2 antibody
    • Neuroblastoma specific potassium channel alpha subunit KvLQT2 antibody
    • Neuroblastoma specific potassium channel protein antibody
    • Neuroblastoma specific potassium channel subunit alpha antibody
    • Neuroblastoma specific potassium channel subunit alpha KvLQT2 antibody
    • Neuroblastoma-specific potassium channel subunit alpha KvLQT2 antibody
    • OTTHUMP00000031681 antibody
    • OTTHUMP00000031682 antibody
    • OTTHUMP00000031684 antibody
    • OTTHUMP00000031685 antibody
    • OTTHUMP00000031686 antibody
    • OTTHUMP00000031687 antibody
    • OTTHUMP00000031689 antibody
    • Potassium voltage gated channel KQT like protein 2 antibody
    • Potassium voltage gated channel KQT like subfamily member 2 antibody
    • Potassium voltage gated channel subfamily KQT member 2 antibody
    • Potassium voltage-gated channel subfamily KQT member 2 antibody
    • Voltage gated potassium channel subunit Kv7.2 antibody
    • Voltage-gated potassium channel subunit Kv7.2 antibody
    see all


  • Anti-KCNQ2 antibody (ab105511) at 1 µg/ml + HepG2 cell lysate at 10 µg

    Predicted band size: 96 kDa

    Gel concentration: 12%


ab105511 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Thank you for your reply. I am very pleased to hear you would like to accept our offer and test ab105511 in IP.

Expiration date: #######

This code will give you: 1 free primary antibody before the expi...

Read More

Thank you very much for your reply.

Following on from our discussions, I am pleased to offer a discount off a future purchase if you buy ab105511 now, test it in IP and submit feedback to us in the form of an Abreview. It doesn't matter whet...

Read More

Thank you for contacting us and for your interest in our products.

I am sorry to confirm that as far as we are aware, ab28778 and ab105511 KCNQ2 antibodies have never been tested in IP. All tested applications covered by the 6 month guarante...

Read More


Sign up